Back to Search Results
Image Place holder

Timothy Kubal, MD, MBA

Interim Chair, Department of Satellite and Community Oncology
Sr. Medical Director, AdventHealth - Wesley Chapel

★★★★★
★★★★★
5 (132 ratings)
Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Leukemia, Myelodysplastic Syndromes (MDS)

Dr. Kubal is an associate member in the Moffitt Cancer Center Malignant Hematology Department. He completed his hematology/oncology fellowship at the University of South Florida at Moffitt Cancer Center, completing an MBA concurrently at the University of South Florida. Dr. Kubal's research and clinical interests are in myeloid malignancies with a particular focus in acute leukemias. In addition to his clinical efforts, Dr. Kubal serves as the medical director of process excellence and is focused on continuous improvement of the patient experience. Dr. Kubal serves as Senior Medical Director of Moffitt at Wesley Chapel, and practices full time at the Moffitt Wesley Chapel campus.


Education & Training

Fellowship:

  • Moffitt Cancer Center/University of South Florida - Hematology/Oncology

Residency:

  • University of North Carolina - Internal Medicine

Medical School:

  • Florida State University College of Medicine - MD
Video Profile
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Mathew S, Kubal T, Tabatabaian F. Worsening hypereosinophilia with use of dupilumab. Ann Allergy Asthma Immunol. 2023 Mar.130(3):272-275. Pubmedid: 36513222.
  • Krause D, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Kennedy K, Austin A, Begue A, Bell R, Raczyk C, Pickard T, Kubal T, Johnson D, Jeffries K, Dest V, Randall R, Sugalski J, Zecha G. Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network's Member Institutions. J Adv Pract Oncol. 2022 Jul.13(5):507-513. Pubmedid: 35910498. Pmcid: PMC9328455.
  • Sugalski JM, Franco T, Shulman LN, Souza E, Hochberg E, Chiang A, Lawrence S, Krause D, Kubal T. COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. J Natl Compr Canc Ne. 2022 Jan.1-4. Pubmedid: 34991065.
  • Li W, Richter K, Lee J, McCarthy K, Kubal T. Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract. 2022 Dec.28(8):1812-1818. Pubmedid: 34609924.
  • Li W, Richter KA, Tobon KA, McCarthy KT, Kubal TE. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. J Oncol Pharm Pract. 2021 Oct.27(7):1684-1690. Pubmedid: 33092499.
  • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
  • Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
  • Sugalski J, Franco T, Shulman LN, Cinar P, Bachman J, Crews JR, Olsen M, Schatz A, Kubal T. Creative Strategies Implemented During the Coronavirus Pandemic That Will Impact the Future of Cancer Care. J Natl Compr Canc Ne. 2020 Oct.1-5. Pubmedid: 33126204.
  • Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clin Pharmacol Ther. 2020 Mar.107(3):563-570. Pubmedid: 31549389. Pmcid: PMC7018540.
  • Talati C, Frantz D, Lubas A, Salamanca C, Tobon K, Kubal T. How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. Future Oncol. 2020 Mar.16(7):281-291. Pubmedid: 31985277.
  • Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Ne. 2020 Apr.1-6. Pubmedid: 32294617.
  • Johnson D, Ouenes O, Letson D, de Belen E, Kubal T, Czarnecki C, Weems L, Box B, Paculdo D, Peabody J. A Direct Comparison of the Clinical Practice Patterns of Advanced Practice Providers and Doctors. Am J Med. 2019 Nov.132(11):e778-e785. Pubmedid: 31145882.
  • Sugalski JM, Kubal T, Mulkerin DL, Caires RL, Moore PJ, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA, Kidd SK, Krause DM, Carlson RW, Stewart FM. National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers. J Oncol Pract. 2019 May.15(5):e458-e466. Pubmedid: 30964732.
  • Colonna S, Sweetenham J, Burgon TB, Buys SS, Lynch R, Au T, Johnson E, Kubal T, Paculdo D, Acelajado MC, Peabody JW. A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clin Breast Cancer. 2019 Apr.19(2):e376-e384. Pubmedid: 30711440.
  • Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: 28006850.
  • Kubal T, Letson DG, Chiappori AA, Springett GM, Shimkhada R, Tamondong Lachica D, Peabody JW. Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers. BMJ Open. 2016 Sep.6(9):e012312. Pubmedid: 27625063. Pmcid: PMC5030551.
  • Kubal T, Peabody JW, Friedman E, Levine R, Pursell S, Letson DG. Using Vignettes to Measure and Encourage Adherence to Clinical Pathways in a Quality-Based Oncology Network: An Early Report on the Moffitt Oncology Network Initiative. Manag Care. 2015 Oct.24(10):56-64. Pubmedid: 26665718.
  • Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014 Oct.21(4):322-327. Pubmedid: 25310213.
  • Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol. 2013 Mar.20(2):100-106. Pubmedid: 23385612.
  • Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Jun.11(2):85-87. Pubmedid: 22169039.
  • Winokur RS, Kubal T, Liu D, Davis SF, Smith BN. Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy. Epilepsy Res. 2004 Feb.58(2-3):93-105. Pubmedid: 15120741.

Patient Comments
Overall Satisfaction
5
★★★★★
★★★★★

132 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments